WO2004035552A1 - Derives d’alpha-phenil acetanilides presentant une activite inhibitrice de l’acat et leur application en therapeutique - Google Patents
Derives d’alpha-phenil acetanilides presentant une activite inhibitrice de l’acat et leur application en therapeutique Download PDFInfo
- Publication number
- WO2004035552A1 WO2004035552A1 PCT/FR2003/003038 FR0303038W WO2004035552A1 WO 2004035552 A1 WO2004035552 A1 WO 2004035552A1 FR 0303038 W FR0303038 W FR 0303038W WO 2004035552 A1 WO2004035552 A1 WO 2004035552A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trimethyl
- phenylacetanilide
- hydroxy
- tetrazolyl
- dodecyl
- Prior art date
Links
- CTRMMQZWUPXORN-UHFFFAOYSA-N CCCCCCCCCCCC[n]1nnc(C(C(OCC)=O)c2ccccc2)n1 Chemical compound CCCCCCCCCCCC[n]1nnc(C(C(OCC)=O)c2ccccc2)n1 CTRMMQZWUPXORN-UHFFFAOYSA-N 0.000 description 1
- UVLYNZHAOWTPSF-UHFFFAOYSA-N Cc(cc(c(C)c1C)NC(C(c2n[n](CCCCCCCCCCCC(F)F)nn2)(c2ccccc2)F)=O)c1O Chemical compound Cc(cc(c(C)c1C)NC(C(c2n[n](CCCCCCCCCCCC(F)F)nn2)(c2ccccc2)F)=O)c1O UVLYNZHAOWTPSF-UHFFFAOYSA-N 0.000 description 1
- FDUUIJIUARVPPJ-NDEPHWFRSA-N Cc(cc(c(C)c1C)NC([C@H](c2ccccc2)SCCCCCCCCCCCC(F)F)=O)c1O Chemical compound Cc(cc(c(C)c1C)NC([C@H](c2ccccc2)SCCCCCCCCCCCC(F)F)=O)c1O FDUUIJIUARVPPJ-NDEPHWFRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Definitions
- the subject of the present invention is new derivatives of ⁇ -phenyl acetanilides, their preparation and their application in human therapy.
- ACAT inhibitor compounds have been previously identified by the Applicant (Patent WO97 / 19918). They have hypocholesterolemic and antioxidant properties allowing them to act on both the quantity and the quality of lipids, thus reducing their atherogenic potential and their long-term deleterious effects on the vascular wall. These compounds however have a low bioavailability and a sensitivity to oxidation limiting the use of formulating agents capable of improving their bioavailability.
- the object of the present invention is to obtain new derivatives having an activity profile comparable to those described by the applicant (WO97 / 19918) with increased bioavailability and chemical and metabolic stability.
- - R represents hydrogen or a fluorine atom - A represents a group
- - n represents an integer from 5 to 11 inclusive terminals
- R, R 5 identical or different, independently represent either hydrogen or a fluorine atom
- the compounds of general formula I having one or more asymmetric centers, the present invention covers the various stereoisomers or enantiomers and their mixtures. These can be obtained by conventional methods such as, for example, chormatographic separation on a chiral column.
- the compounds of general formula I can be used for the preparation of pharmaceutical compositions or of medicaments intended for the treatment of diseases such as hypercholesterolemia and atherosclerosis.
- the compounds of the present invention unexpectedly exhibit cholesterol-lowering activity in vivo superior to the compounds described above.
- the compounds of general formula I can be obtained by treatment of an aniline IN, optionally hydrochloride, with the derivative N, the groups R 1s R, R 3 and A having the same meaning as above, in the presence of an activator such as dicyclohexylcarbodiimide or iodide of 2-chloro-1-methyl pyridinium and triethylamine.
- an activator such as dicyclohexylcarbodiimide or iodide of 2-chloro-1-methyl pyridinium and triethylamine.
- IV aromatic amines are commercial or can be obtained by synthetic methods known to those skilled in the art.
- Nile compounds for which R 4 and R 5 represent a fluorine atom can be prepared by DAST fluorination of bromoaldehyde NUI then reaction of the derivative obtained on the thiomandelic ester IX.
- Example 1 The invention may be illustrated with the aid of the nonlimiting examples which follow and which constitute advantageous embodiments of the compounds of the invention.
- Example 1 The invention may be illustrated with the aid of the nonlimiting examples which follow and which constitute advantageous embodiments of the compounds of the invention.
- the aldehyde (8.74 g; 0.033 mole) is taken up in methylene chloride (170 ml) and added dropwise to diethyl aminosulfide trifluoride (DAST) (5.3 ml; 0.04 mole) in chloride of methylene (120 ml).
- DAST diethyl aminosulfide trifluoride
- This compound is prepared according to the method described in Example 2c using the compound 3c obtained above in place of the compound 2b.
- This compound is prepared according to the method described in Example 2c using the compound 4c obtained above in place of the compound 2b.
- This compound is prepared according to the process described in Example 4b, replacing the dodecyl bromide by the 1-bromo-12,12-difluorododecane obtained as described in Example 2a.
- This compound is obtained according to the process described in Example 2c by replacing 2,3,5-trimethylaminophenol by 2,3,5,6-tetramethyl phenylene diamine and ⁇ - (12,12- difluorododecylthio) phenylacetic acid. with ⁇ - (2-hexyl-2H-5-tetrazolyl) phenyl acetic acid.
- compound 12 After sahfication with hydrochloric acid in isopropanol, compound 12 is obtained by precipitation with ethyl ether.
- Rf 0.48 (CH 2 C1 2 - AcOEt 80-20)
- the compounds of the invention have been subjected to pharmacological tests which have shown their potential interest in the treatment of hypercholesterolemia and in the treatment of atheromatous disease.
- ACAT acyl COA enzyme: cholesterol O acyl transferase
- Male rats (160-180 g) are subjected for 4 days to an altromin C 1061 hypercholesterolemic diet and treated in parallel by oral route with the compounds in suspension in a solution of Tween 80 at 2% in distilled water.
- the effective dose 50 corresponds to the dose which halves the plasma cholesterol concentration compared to the control animals.
- the compounds of the invention are powerful cholesterol-lowering agents, ACAT inhibitors which can be used in the treatment of diseases such as hypercholesterolemia and atherosclerosis.
- compositions can be presented in the form suitable for oral, parenteral or local administration, for example in the form of capsules, tablets, granules, capsules, liquid solutions, syrups, oral suspensions and contain the appropriate excipients.
- the daily dosage can range from 5 to 1000 mg.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004544391A JP2006512302A (ja) | 2002-10-16 | 2003-10-15 | ACAT阻害活性を有するα−フェニルアセトアニリド誘導体およびその治療的適用 |
EP03780228A EP1558590A1 (fr) | 2002-10-16 | 2003-10-15 | Derives d'alpha-phenyl acetanilides presentant une activite inhibitrice de l'acat et leur application en therapeutique |
US10/531,234 US20060135785A1 (en) | 2002-10-16 | 2003-10-15 | Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof |
CA002502505A CA2502505A1 (fr) | 2002-10-16 | 2003-10-15 | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
AU2003288327A AU2003288327A1 (en) | 2002-10-16 | 2003-10-15 | Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof |
BR0315347-9A BR0315347A (pt) | 2002-10-16 | 2003-10-15 | Derivados de alfa-fenil acetanilidas e sua aplicação em terapêutica humana |
MXPA05004064A MXPA05004064A (es) | 2002-10-16 | 2003-10-15 | Derivados de alfa-fenil acetanilida que tienen una actividad inhibidora de acil coa colesterol o-acil transferasa y la aplicacion terapeutica de los mismos. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0212855A FR2845991B1 (fr) | 2002-10-16 | 2002-10-16 | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
FR02/12855 | 2002-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004035552A1 true WO2004035552A1 (fr) | 2004-04-29 |
Family
ID=32050433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/003038 WO2004035552A1 (fr) | 2002-10-16 | 2003-10-15 | Derives d’alpha-phenil acetanilides presentant une activite inhibitrice de l’acat et leur application en therapeutique |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060135785A1 (fr) |
EP (1) | EP1558590A1 (fr) |
JP (1) | JP2006512302A (fr) |
CN (1) | CN1705648A (fr) |
AU (1) | AU2003288327A1 (fr) |
BR (1) | BR0315347A (fr) |
CA (1) | CA2502505A1 (fr) |
FR (1) | FR2845991B1 (fr) |
MX (1) | MXPA05004064A (fr) |
WO (1) | WO2004035552A1 (fr) |
ZA (1) | ZA200502694B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741966B2 (en) | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
EP2147910A1 (fr) * | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Nouveaux composés lipidiques |
KR101783817B1 (ko) | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
CN107496395A (zh) | 2010-11-05 | 2017-12-22 | 普罗诺瓦生物医药挪威公司 | 使用脂质化合物的治疗方法 |
ES2748562T3 (es) | 2013-02-28 | 2020-03-17 | Basf As | Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma |
CA2983377C (fr) | 2015-04-28 | 2023-08-29 | Pronova Biopharma Norge As | Utilisation d'acides gras structurellement ameliores contenant du soufre pour prevenir et/ou traiter la steatose hepatique non alcoolique |
CN105418527A (zh) * | 2015-12-28 | 2016-03-23 | 青岛友诚高新技术有限公司 | 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途 |
CN105541741A (zh) * | 2016-01-14 | 2016-05-04 | 青岛友诚高新技术有限公司 | 一种具有治疗冠心病活性的化合物及其制备方法 |
IL308604A (en) | 2017-12-06 | 2024-01-01 | Basf As | Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease |
WO2022115207A1 (fr) * | 2020-11-25 | 2022-06-02 | Trustees Of Dartmouth College | Méthode permettant d'atténuer la neuroinflammation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993004052A1 (fr) * | 1991-08-22 | 1993-03-04 | Warner-Lambert Company | Inhibiteurs d'acat a base de tetrazole d'amide |
WO1997019918A1 (fr) * | 1995-11-28 | 1997-06-05 | Pierre Fabre Medicament | Nouveaux derives de 2,3,5 trimethyl-4-hydroxy anilides, leur preparation et leur application en therapeutique |
-
2002
- 2002-10-16 FR FR0212855A patent/FR2845991B1/fr not_active Expired - Fee Related
-
2003
- 2003-10-15 CN CNA2003801016613A patent/CN1705648A/zh active Pending
- 2003-10-15 US US10/531,234 patent/US20060135785A1/en not_active Abandoned
- 2003-10-15 AU AU2003288327A patent/AU2003288327A1/en not_active Abandoned
- 2003-10-15 JP JP2004544391A patent/JP2006512302A/ja active Pending
- 2003-10-15 BR BR0315347-9A patent/BR0315347A/pt not_active Application Discontinuation
- 2003-10-15 MX MXPA05004064A patent/MXPA05004064A/es unknown
- 2003-10-15 EP EP03780228A patent/EP1558590A1/fr not_active Withdrawn
- 2003-10-15 WO PCT/FR2003/003038 patent/WO2004035552A1/fr not_active Application Discontinuation
- 2003-10-15 CA CA002502505A patent/CA2502505A1/fr not_active Abandoned
-
2005
- 2005-04-04 ZA ZA200502694A patent/ZA200502694B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993004052A1 (fr) * | 1991-08-22 | 1993-03-04 | Warner-Lambert Company | Inhibiteurs d'acat a base de tetrazole d'amide |
WO1997019918A1 (fr) * | 1995-11-28 | 1997-06-05 | Pierre Fabre Medicament | Nouveaux derives de 2,3,5 trimethyl-4-hydroxy anilides, leur preparation et leur application en therapeutique |
Also Published As
Publication number | Publication date |
---|---|
JP2006512302A (ja) | 2006-04-13 |
EP1558590A1 (fr) | 2005-08-03 |
US20060135785A1 (en) | 2006-06-22 |
FR2845991B1 (fr) | 2005-02-04 |
MXPA05004064A (es) | 2005-06-08 |
CA2502505A1 (fr) | 2004-04-29 |
AU2003288327A1 (en) | 2004-05-04 |
ZA200502694B (en) | 2005-11-10 |
FR2845991A1 (fr) | 2004-04-23 |
CN1705648A (zh) | 2005-12-07 |
BR0315347A (pt) | 2005-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0506532A1 (fr) | Nouveaux dérivés de l'indole, procédé de préparation et médicaments les contenant | |
EP0202157A1 (fr) | Amino-2 thiazoles N-substitués, leur procédé de préparation et leur application en thérapeutique | |
EP1558590A1 (fr) | Derives d'alpha-phenyl acetanilides presentant une activite inhibitrice de l'acat et leur application en therapeutique | |
EP0073161A1 (fr) | Nouveaux dérivés de la pyrazine actifs sur le système nerveux central | |
CH646687A5 (fr) | Derives de l'acide cyclohexane carboxylique. | |
EP0021940B1 (fr) | Nouveaux dérivés aminés du benzothiazole, leur procédé de préparation et leur application en thérapeutique | |
EP0533827B1 (fr) | Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
FR2707638A1 (fr) | Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique. | |
CH639078A5 (fr) | Amides derives d'acides carboxyliques-5 pyrimidiniques, leur preparation et medicaments les contenant. | |
BE1006419A3 (fr) | Derives du cycloheptimidazole, procede de preparation de ces derniers et agents therapeutiques contenant ces composes. | |
EP0459887A1 (fr) | Dérivés N-pyrazolyl-ortho-dialkyl-benzamide doués d'activité anticonvulsivante, procédé de préparation et composition pharmaceutique | |
EP0143016B1 (fr) | Dérivés de 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-N-phényl acétamide, leur préparation et leur application en thérapeutique | |
EP0301936A1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique | |
BE890948A (fr) | Derives de l'acide anthranilique | |
EP0233801B1 (fr) | Nouveaux amides substitués, leur préparation et les compositions pharmaceutiques qui les contiennent | |
CA1076117A (fr) | Procede d'obtention de nouveaux ethers aryliques et les produits en resultant | |
FR2670780A1 (fr) | Derives de 4-(acylamino)benzopyranes, leur preparation et leur application en therapeutique. | |
EP0613470B1 (fr) | Nouveaux derives de cinnolinones-4, leur preparation et leur application en therapeutique | |
FR2757158A1 (fr) | Nouveaux derives d'acide 4-(1-piperazinyl) benzoique, leur procede de preparation et leurs applications therapeutiques | |
EP0663903B1 (fr) | Derives de dihydro-1,2 oxo-2 amino-3 quinoxalines, leur preparation et leur application en therapeutique | |
EP0106860B1 (fr) | Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant | |
EP0871611B1 (fr) | Nouveaux derives de glycylanilides, leur preparation et leur application en therapeutique | |
EP0125975B1 (fr) | Diphénylazométhines portant une chaîne esterifiée, leur préparation et leur application en thérapeutique | |
CA1095039A (fr) | Procede d'obtention de nouveaux ethers aryliques et les produits en resultant | |
EP0151052A2 (fr) | Aminoéthylimidazole, composition pharmaceutique en contenant et procédé de préparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP MX US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003288327 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/02694 Country of ref document: ZA Ref document number: 200502694 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/004064 Country of ref document: MX Ref document number: 2502505 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004544391 Country of ref document: JP Ref document number: 20038A16613 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003780228 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003780228 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006135785 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10531234 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10531234 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003780228 Country of ref document: EP |